

North America's Stand In Pharmaceutical Manufacturing

All facilities compete against each other for business.

It seems that many decisions to shut down production of pharmaceutical facilities in North America is based on "perceived" cost savings.

Recent interventions of the FDA at many foreign sites indicates that perhaps patients taking some of these products are at much higher risk.

The question is how profitable is it have a plant shut down by the FDA or to have a product recall ?

As concerned North Americans we need to concentrate on allowing only safe products to be allowed as imports.

Keeping the highest standards of manufacturing and packaging here locally while being competitive against legitimate foreign imports is key to our future.

Sadly, in the end, it will be the financial losses through litigation for the supply of substandard drugs that will lead the business back to us.

Let's do our best to make sure our products are the best quality and value in the world and become the viable alternative.